These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
23. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431 [TBL] [Abstract][Full Text] [Related]
24. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889 [TBL] [Abstract][Full Text] [Related]
25. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis. Nagabushan H; Roopadevi HS J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373 [TBL] [Abstract][Full Text] [Related]
26. Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment. Mokrousov I; Akhmedova G; Molchanov V; Fundovnaya E; Kozlova E; Ostankova Y; Semenov A; Maslennikova N; Leontev D; Zhuravlev V; Turkin E; Vyazovaya A Clin Microbiol Infect; 2021 Mar; 27(3):478-480. PubMed ID: 32891766 [No Abstract] [Full Text] [Related]
27. TMC207 becomes bedaquiline, a new anti-TB drug. Palomino JC; Martin A Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736 [TBL] [Abstract][Full Text] [Related]
28. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153 [TBL] [Abstract][Full Text] [Related]
29. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis. Bouton TC; de Vos M; Ragan EJ; White LF; Van Zyl L; Theron D; Horsburgh CR; Warren RM; Jacobson KR PLoS One; 2019; 14(10):e0223308. PubMed ID: 31622366 [TBL] [Abstract][Full Text] [Related]
30. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469 [TBL] [Abstract][Full Text] [Related]
31. A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis. Deng G; Fu L Lancet Infect Dis; 2024 Sep; 24(9):940-941. PubMed ID: 38768618 [No Abstract] [Full Text] [Related]
32. A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Köser CU; Miotto P; Ismail N; Anthony RM; Utpatel C; Merker M; Niemann S; Tahseen S; Rigouts L; Rodrigues C; Omar SV; Farhat MR; Antonenka U; Hoffmann H; Cirillo DM; Schön T Eur Respir J; 2024 Jul; 64(1):. PubMed ID: 38991722 [TBL] [Abstract][Full Text] [Related]
33. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report. Park S; Lee KM; Kim I; Mok J Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076 [TBL] [Abstract][Full Text] [Related]
34. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Pontali E; D'Ambrosio L; Centis R; Sotgiu G; Migliori GB Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331046 [No Abstract] [Full Text] [Related]
35. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis. Patel RV; Riyaz SD; Park SW Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806 [TBL] [Abstract][Full Text] [Related]
36. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862 [TBL] [Abstract][Full Text] [Related]
37. Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis. Perumal R; Bionghi N; Nimmo C; Letsoalo M; Cummings MJ; Hopson M; Wolf A; Jubaer SA; Padayatchi N; Naidoo K; Larsen MH; O'Donnell M Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945030 [TBL] [Abstract][Full Text] [Related]
38. Bedaquiline: Introducing a new drug to the MDR TB armamentarium. Kambili C Indian J Tuberc; 2016 Jul; 63(3):137-138. PubMed ID: 27865232 [No Abstract] [Full Text] [Related]
39. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Nimmo C; Millard J; Brien K; Moodley S; van Dorp L; Lutchminarain K; Wolf A; Grant AD; Balloux F; Pym AS; Padayatchi N; O'Donnell M Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32060065 [TBL] [Abstract][Full Text] [Related]
40. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. Jang JC; Jung YG; Choi J; Jung H; Ryoo S J Microbiol; 2017 Jun; 55(6):483-487. PubMed ID: 28429168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]